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ABSTRACT
Aim:	  To estimate and compare serum β2-microglobulin levels in  oral leukoplakia and  oral squamous cel 
carcinoma patients with that of control group.
Material	   and	   Methods:	  The study  was carried  out  on 70 subjects  divided into three  groups (20  oral 
leukoplakia  patients, 30  oral squamous cel carcinoma  patients and 20 controls). Serum β2-microglobulin was 
estimated by an enzyme linked immunosorbent assay (ELISA).
Results:	  A significant increase in serum levels  of β2-microglobulin  was  observed in  oral squamous cel 
carcinoma patients as compared to control group.
Conclusions:	  Results  of this study suggest that estimation  of serum β2-microglobulin can  be  useful in as 
biomarker for diagnosis of oral squamous cel carcinoma.
KEYWORDS:	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INTRODUCTION
  Squamous cel carcinoma is the 
most common  malignancy  of  oral cavity 
r e p r e s e n t i n g 9 0 - 9 5 %  o f a l l o r a l 
malignancies in India1. It is a  major 
health  problem in India, forming about 
10%  of the  new cancers that  occurs in al 
parts  of  body each year1. The current 
research focuses  on faster, specific and 
sensitive tests to  detect cancer in early 
stages. In this context,  many tumor 
markers  have  been studied2. In the 
oncogenic  process, specific events  occur 
at each step and these can  be studied  by 
assessing the associated  biological 
markers3.
 The tumor markers are 
substances that are  produced  by  body in 
response to cancerous  growth  or  by the 
cancer tissue itself and released in  blood 
and  other  body fluids.  There are  only a 
few  wel-established tumor  markers that 
are  being routinely  used like  prostate 
specific antigen (PSA), α-fetoprotein for 
hepatocellular carcinoma, cancer 
antigen-125 for  ovarian cancer etc4. For 
the  detection  of  oral  malignancy various 
markers like  oncofoetal  protein, 
carcinoembryonic antigen (CEA),  other 
proteins like  B-Protein  & β2 
microglobulin , and enzymes like lactate 
dehydrogenase (LDH)5. These  markers 
have  wide range of potential applications 
like screening,  diagnosis,  prognosis, and 
monitoring the response to treatment. 
 The search for "ideal tumour 
marker" has become a major goal in 
research oncology6. 
 β2-microglobulin is a tumor 
marker, which has received considerable 
attention. It was described and isolated 
from the urine of patients with tubular 
proteinurias by Berggard and Bearn7.  
 Scully8 was the first to assess the 
potential use of β-2 micro globulin as a 
marker in oral premalignant lesions. β2 
microglobulin is low molecular mass 
protein and which is present in 
membranes of possibly all nucleated cells 
where it appears to be present in 
s t r u c t u r a l a s s o c i a t i o n w i t h t h e 
histocompatibility antigen (HCA)9,10. 
 Studies have reported increased 
β2-microglobulin in various malignancies 
like myelomas, acute and chronic 
leukemia, Non-Hodgkin’s lymphoma, 
melanoma, carcinomas of breast, lung, 
colon, stomach, cervix and uterus11,12. The 
increased β2-microglobulin is reported in 
patients with oral malignancies as 
well13-15.
 Early detection of oral cancer is 
important to reduce morbidity and 
mortality. Plasma biomarkers are 
thought to have a great potential for 
assisting the early detection of oral 
c a n c e r a n d m o n i t o r i n g c a n c e r 
progression or recurrence16. The 
advantage of early detection, before 
lymph node involvement is shown by the 
70 percent 5 year survival rate of patients 
who do not have nodal involvement. This 
is in marked contrast to the 30 percent 5 
year survival rate of patients whose 
diagnosis is established after nodal 
disease exists. Very few studies have been 
carried out related to serum β2-
microglobulin in oral cancer and 
precancer. Considering the high 
prevalence of oral malignancy in India, 
the present study was carried out to 
estimate and compare serum β2-
microglobulin levels in patients with oral 
squamous cell carcinomas and in 
patients with oral leukoplakia with that 
of healthy controls.
MATERIAL AND METHODS
 For the present study, 70 
patients were selected at random from 
Department of Oral Medicine and 
Radiology, Govt. Dental College, Nagpur, 
Maharashtra, India. The informed 
consent was obtained from all patients 
and ethical clearance was obtained from 
institutional ethical committee. The 
patients were divided into three groups: 
G1: control group consisted of 20 age and 
sex matched individuals who gave no 
history of any habit nor presented with 
any signs of systemic disease or 
pathological oral lesions; G2: consisted of 
20 patients in age range of 21 to 69 years, 
with clinically and histopathologically 
confirmed leukoplakia; G3: consisted of 
30 patients in age range of 25 to 70 years, 
w i t h c l i n i c a l l y s t a g e d a n d 
histopathologically confirmed squamous 
cell carcinoma of oral cavity.
 None of the patients had 
received any treatment before study and 
were free from conditions where β2-
microglobulin level may be elevated 
(acute and chronic leukemia, non 
hodgkins lymphoma, multiple myeloma, 
tumors of breast, lung, colon, cervix, 
uterus, hepatobiliary disorders & 
systemic lupus erythematosus). To avoid 
false positive results, care was taken to 
exclude subjects with other malignancies 
or with history of systemic diseases.
 Under aseptic conditions, five 
ml of b lood was col lected from 
anticubital vein and allowed to clot at 
room temperature for two hours and 
t h e n s e r u m w a s s e p a r a t e d b y 
centrifuging at 3000 rpm for 10 minutes. 
 The serum was stored in Laxbro 
storage vials at –700C until assayed β2-
microglobulin was estimated by an 
indirect solid phase Enzyme Linked 
Immunosorbent Assay (ELISA), which 
was designed for the quantitative 
measurement of β2-microglobulin in 
human serum. Quantitative estimation 
of serum β2-microglobulin was done 
u s i n g I m m u n o m e t r i c E n z y m e 
Immunoassay kit manufactured by 
Orgentec Diagnostika GmbH, Mainz, 
Germany.
 The data was analyzed by using 
statistical package for social sciences 
(SPSS) software. Cases and controls were 
tested for statistical significance by 
Students’ unpaired t-test. Values of 
p<0.05 were considered significant. 
Analysis of variance (ANOVA) was used 
to compare β2-microglobulin in various 
age groups of control group.
RESULTS
 Mean serum β2-microglobulin 
level in control group was1.88 µg/ml with 
standard deviation of 0.82, it was 2.23 ± 
0.84  µg/ml in oral leukoplakia group and 
3.23± 0.96 µg/ml in oral squamous cell 
carcinoma group (Table 1). The increase 
in serum β2-microglobulin level in oral 
carcinoma group compared with control 
group was statistically highly significant 
(p<0.001). Statistically significant 
increase was also found when oral 
squamous cell carcinoma group was 
compared with oral leukoplakia group 
( p < 0 . 0 5 ) . T h o u g h , i n c r e a s e d β2 -
microglobulin levels were observed in 
oral leukoplakia, it was not found to be 
significant when it was compared with 
control group (P>0.05) (Table 2). Serum 
β2-Microglobulin levels were also found 
to be increasing with advancing age in 
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control group. This increase was 
statistically highly significant (Table 3).
 In control group the mean 
serum β2-microglobulin level in females 
was 1.7 ± 0.50 µg/ml and in males it was 
2.07 ±1.04 µg/ml which was higher than 
in females, but found to be statistically 
non-significant (Table 4).
Table 1. Serum levels of β2-microglobulin in various groups.
Sr. No.        Groups β2-microglobulin  (µg/ml) Mean +SD
1 Group I [Controls (n= 20)] 1.88µg/ml  ±0.82
2 Group II [Oral Leukoplakia (n=20)] 2.23 µg/ml ±0.84  
3 Group III [Oral squamous cell carcinoma (n=30)] 3.23µg/ml ±0.96
Table 2. Comparison of serum levels of β2-microglobulin between various groups.
Parameter T-value P-value Significance of P-value
1 Control versus oral squamous cell carcinoma 5.35 p< 0.001** Highly significant
2 Oral leukoplakia versus oral squamous cell carcinoma 3.84 p<0.05* Significant
3 Control versus oral leukoplakia 1.34 p>0.05 Non- Significant
*Stands for p < 0.05, **stands for p < 0.001.
Table 3. Mean serum β2-microglobulin level in various age groups in control group.
Sr. No. Age Groups in years Mean Serum β2-microglobulin level (µg/ml)
1 21-30 years 1.17 ± 0.35
2 31-40 years 1.55 ± 0.23
3 41-50 years 1.55 ± 0.31
4 51-60 years 2.32 ± 0.43
5 61-70 years 2.82 ± 1.18
Table 4. Mean serum beta-2 microglobulin level in males and females in control group.
Mean Serum β2-microglobulin in females of 
Control group with SD
Mean Serum β2-microglobulin in males  of Control 
group with SD p-value
1.7 ± 0.50 2.07 ± 1.04 p>0.05
DISCUSSION
 In present study, increased 
mean serum β2-microglobulin level in 
oral squamous cell carcinoma patients 
as compared to control group was 
found. This is in accordance with 
studies by- Scully13, Lin17, Vinzez et al.2, 
Manzar et al.14, Anil et al.18, Delphine 
Silva et al.19 and Singh20. However, 
Wennerberg et al.15 reported that only 
12% of patients with oral squamous cell 
carcinoma had elevated serum β2- 
microglobulin.  T e a s d a l e e t a l . 2 1 
reported that serum β2-microglobulin 
more than 3 mg/l are frequently 
a s s o c i a t e d w i t h a d v a n c e d a n d 
persistent malignant disease even after 
allowing for the effects of age and non-
specific illness. No correlation between 
various stages of oral squamous cell 
carcinoma and serum β2-microglobulin 
level could be established. This is in 
accordance with Vinzez et al.2 and 
Manzar et al.14. However, Delphine 
Silva19 reported that progressively 
higher values were obtained as the oral 
squamous cell carcinoma advanced 
clinically. There was increase in mean 
serum β2-microglobulin levels in oral 
leukoplakia group as compared with 
control group. This is in accordance 
with Scully13 and Anil et al18.
 When serum β2-microglobulin 
level was compared between various 
age groups of control, it was observed 
that values increased with the 
advancing age and this difference was 
statistically highly significant, however 
no co-relation between age and serum 
β2-microglobulin could be established 
in oral squamous cell carcinoma group. 
These finding were consistent with 
study of Teasdale et al.21 and Parildar22. 
In control group, mean serum β2-
microglobulin level in male patients 
was higher compared to female 
patients of same group however 
statistically it was not significant. This 
finding is in contrast with Teasdale et 
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al.21, who found mean serum β2-
microglobulin levels consistently 
higher in females than males. The 
increased β2-microglobulin levels 
reflect a heightened level of immune 
activation as reported by Wanchu et al.
23 in a study of HIV/TB co-infection. 
Also increased serum β2-microglobulin 
levels are reported in old age which 
a g a i n r e f l e c t s d e c r e a s e d h o s t 
immunity. These findings prompt us to 
think that malignancies either develop 
in immunocompromised host or there 
is immune deficiency secondary to 
malignant process.
 In the present study, following 
findings were also noted which were 
not the objectives of study. These are 
(oral carcinoma group had 30 patients) 
20 males and 10 females and in oral 
leukoplakia group, out of 20 patients, 
only 1 was female. From this, it can be 
concluded that oral pre-cancer and 
cancer are more common in males 
which can be attributed to relatively 
higher indulgence of males in tobacco 
and alcohol habits in India. Out of 30 
oral carcinoma patients, only two 
patients had stage I, 4 patients had 
stage II and 24 patients had stage III 
and stage IV oral squamous cell 
carcinoma. The most common habit 
was tobacco plus lime chewing in both 
oral squamous cell carcinoma and oral 
leukoplakia group. In both oral 
leukoplakia and oral squamous cell 
carcinoma group elderly patients were 
affected most. The mean age in oral 
leukoplakia group was 46.45 ± 14.77 
years and in oral carcinoma group 
mean age was 46.47 ± 9.96 years.
CONCLUSIONS
 Decreased mortality and 
morbidity can be achieved in oral 
cancer and pre-cancer by identification 
of tumor bio-markers which assist in 
early diagnosis and monitoring of 
progression of disease. This study 
c o n f i r m s t h e r e s u l t s o f o t h e r 
investigators, that β2-microglobulin 
levels are increased with progression 
from precancer to oral cancer. From 
the results presented it can be 
concluded that β2-microglobulin can be 
used as an adjunct to clinic-pathogical 
diagnosis or in combination assay 
along with other relevant tumor 
markers in diagnosis of oral squamous 
cell carcinoma. Further studies are 
necessary to find out whether serum 
β2-microglobulin would be of help as 
an individual tumor marker in clinical 
diagnosis.
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